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MicroRNAs (miRNAs) are a broad class of non-coding RNAs nearly 21 nucleotides length, which play crucial functions in post-
transcriptional gene regulation. These molecules are associated with many developmental and cellular processes in eukaryotic 
organisms. Current investigation has reported major factors contributing to miRNA biogenesis and has constituted basic principles 
of miRNA function. More recently, it was confirmed that various miRNAs are clearly implicated in human malignancies, such as lung, 
breast, ovarian, bladder, colon cancer and other kinds of carcinoma. In addition, dysregulation in the miRNA machinery elements 
such as Dicer, Drosha, DGCR8, Argonaut, and TRBP could be involved in the progress of many tumor types. The purpose of the 
current review was to compile growing information besides how miRNA biogenesis and gene silencing are modified to develop cancer.
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Several types of short non-coding RNAs including 
small interfering RNAs (siRNAs), Piwi-interacting RNAs 
(piRNAs) and microRNAs (miRNAs) have a principal 
and crucial regulatory functions of development pro-
cesses in all eukaryotes [1]. Formerly, a finding re-
vealed the first miRNAs in Caenorhabditis elegans [2]. 
miRNAs are extremely protected from species and 
supposedly may regulate up to 30% of all genes in the 
human genome [3, 4]. miRNAs are small noncoding 
RNAs of 18–24 nt in length that controls gene expres-
sion post-transcriptionally [5] via negative regulation 
through binding to the 3'-untranslated region (3'-UTR) 
of mRNA transcripts, stimulating translational suppres-
sion or break of the target [6, 7]. Multiple thousands 
of miRNAs have been classified in humans and they are 
evolutionarily conserved. Lately, it has been uncovered 
that variable expression of special miRNA genes could 
be increased during the beginning and improvement 
of cancer [8]. Accordingly, cancer-associated al-
terations in miRNA expression models are emerging 
as promising diagnostic markers often compared 
with disease improvement and survival rates, thus 
offering a new window for treatment of another can-
cer types [9]. In general, miRNAs can control several 
processes, including metabolism, cell differentiation, 
proliferation and survival, inflammation, genome sta-
bility, tumor invasion and angiogenesis [10]. Appearing 
in the cell nucleus, miRNA operation on the regula-
tion of gene expression continues in the cytoplasm 
by binding to its supplementary base-sequence of the 
targeted mRNA molecule. Subsequently, gene silenc-
ing through degradation of target mRNA or inhibition 
with the translation process takes its place [11]. Pres-
ently hundreds of miRNAs have been distinguished 
in different species [12]. Notwithstanding, most 
miRNA research is focused on the growth and progress 
of stem cells, differentiation, tumorigenesis and other 
pathological processes [13].
miRNA BIOGENESIS AND MECHANISM 
OF ACTION
Mainly, miRNAs are encoded within the genome 
and are transcribed by RNA polymerase II (Pol II) 
or RNA polymerase III (Pol III) as long precursor 
transcripts, known as primary miRNAs (pri-miRNAs) 
of several kilobases (kb) in length [14]. Mature miRNAs 
are produced from pri-miRNAs by sequential process-
ing strategies. Conventionally animal pri-miRNAs pos-
sess nearly 33 bp stem and have a terminal loop struc-
ture with flanking segments [15]. Precursor miRNAs 
(pre-miRNAs) are commonly the microprocessor 
system in the nucleus, whose core components are 
the RNase III enzyme Drosha and its binding partner 
DiGeorge syndrome critical region 8 (DGCR8) [16]. 
Approximately 31% of miRNAs are prepared from 
introns of protein-coding genes, whereas many other 
miRNAs are expressed from committing miRNA gene 
loci. An own pri-miRNA can either produce a single 
miRNA or contain clusters of two or more miRNAs that 
are changed from a regular primary transcript [17]. 
However, these long pri-miRNAs are cleaved by Micro-
processor, comprising the double-stranded RNase III 
enzyme Drosha and its crucial cofactor, the double-
stranded RNA binding protein DGCR8 [18]. In this 
pathway, the nuclear splicing machinery supplies 
pre-miRNA from introns. miRNAs originated from this 
process are appropriately termed mirtrons. These 
molecules enclose a short class of miRNAs, but are 
identified in multiple organisms [19]. Preliminary, the 
nuclear microprocessor complex identifies the miRNA 
hairpins in the main transcript and cleaves each hair-
pin roughly 11 nucleotides from its base [20]. Recent 
manifestation suggests that some miRNAs that survive 
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within introns, the so-called mirtrons, bypass Drosha 
break and depend on the proceeding of the pre-mRNA 
splicing machinery to originate an approximately 
60 nt pre-miRNA hairpin [21]. Regardless of whether 
the pre-miRNA hairpin is excised from the initial 
transcript by canonical Drosha break or through the 
mirtron pathway, the next stage in the miRNA biogen-
esis is recognition of the nearly 60 nt pre-miRNA by ex-
portin-5 (XPO5) and export to the cytoplasm in a ran 
guanine triphosphatase-dependent manner [22]. 
Mirtrons encompass a small cluster of miRNAs, but 
are found in numerous organisms. Pre-miRNAs are 
transported from the nucleus to the cytoplasm by the 
exportin-5/RanGTPheterocomplex [23]. Complex 
in cytoplasm compromised of Dicer RNase III endo-
nuclease, transactivation-responsive RNA-binding 
protein (TRBP), and protein kinase Re-activating. 
Protein further cleaves the pre-miRNA generating 
a short double-stranded miRNA:miRNA complex 
intermediate [24]. In the cytoplasm, pre-miRNAs are 
processed by RNase III enzyme Dicer. Dicer is thought 
to react with dsRBDs-containing partner proteins, HIV 
TRBP and/or PKR activating protein (PACT) [25]. Then, 
Dicer cleaves pre-miRNAs into 21–25 nt long miRNA/
miRNA duplexes, each strand of which bears 5' mono-
phosphate, 3' hydroxyl group and a 3' 2-nt overhang. 
It preferentially incorporates one of the duplex strands 
into the RNA-induced silencing complex (RISC). 
Of a miRNA/miRNA duplex, only one strand, designat-
ed the miRNA strand, is selected as the guide of mature 
RISC, whereas the other strand, the miRNA strand, 
is discarded during RISC assembly [26]. Such biased 
strand selection depends on the stability of at least 
three properties of a miRNA/miRNA duplex: the struc-
ture; the 5' nucleotide identity; and the thermodynamic 
asymmetry [27]. These findings propose miRNA pro-
cessing by Dicer, during RISC loading, and target RNA 
cleavage by argonaute 2 (Ago2) is coupled [28]. The 
translational repression mechanism by miRNAs has 
been poorly understood. Recently, it was declared 
that the target mRNAs binding to RISC through partial 
base pairing, are accumulated in the cytoplasmic foci 
referred to as processing bodies (P-bodies). P-bodies, 
in which the mRNAs are stored or degraded by the 
decapping enzymes and exonucleases, do not contain 
the translational machinery [29] (Figure).
DICER
Dicer, a critical RNase III endonuclease of the 
miRNA processing, performs a role in carcinogenesis 
and various types of human malignancies [30]. Dicer 
is a large multi-domain protein with a principal func-
tion for the last step of miRNA and short-interfering 
RNA biogenesis. In human and mouse cell lines, 
Dicer is considered to act in the nuclear clearance 
of dsRNA as well as the foundation of chromatin agree-
ments [31]. Dicer is supposed to play an essential 
function in the biogenesis of eukaryotic small RNAs/
miRNAs; Dicer target transcripts have not been directly 
mapped. Interestingly, mainly Dicer-binding sites 
remain on mRNAs/lncRNAs and are not substantially 
prepared into miniature RNAs. These passive sites 
normally harbor short, Dicer-bound hairpins with 
entire transcripts and regularly maintain target ex-
pression [32]. Dicer, single of the proteins implicated 
in the synthesis miRNA, is implicated in the biogenesis 
of miRNAs and is influential in carcinogenesis and 
cancer progress and progression [33]. Low expression 
of Dicer gene and protein linked to poor prognosis and 
recurrence of cervical cancer.
In addition, the investigation revealed that de-
creased Dicer gene expression and protein levels are 
associated with metastasis relapse and tumor stage. 
The patients with decreased Dicer miRNA and protein 
expression displayed a shorter 5-year disease-free 
survival and overall survival. Moreover, low expression 
of Dicer befits to be a significant prognostic factor 
for cervical malignancy and other tumor types [34]. 
Previous studies have shown that inhibition of Dicer 
in von Hippel — Lindau deficient clear cell renal cell 
carcinoma contributed to the high levels of the hy-
poxia-inducible factors-2α and a cancer phenotype, 
which suggests Dicer could be a useful therapeutic 
target for managing this disease [35]. miR-200a and 
miR-31 are targeted for Dicer and are involved in the 
carcinogenesis, cell migration, and behavior of castra-
tion-resistant prostate cancer, showing that they could 
be possible biomarkers for monitoring of prostate 
cancer progression [36]. The Dicer protein expres-
sion is significantly associated with hormone recep-
tor status and cancer subtype in breast tumors [37]. 
Drosha and Dicer1 mutations impair expression 
of tumor-suppressing miRNAs, including the let-7 fam-
ily, significant regulators of MYCN, LIN28 and other 
Wilms tumor oncogenes. Current findings explored the 
mechanisms through which mutations in miRNA bio-
genesis components reprogrammed miRNA expres-
Figure. Schematic presentation of the miRNA biogenesis and 
functional mechanisms. The miRNA genes are transcribed 
by RNA polymerase II (Pol II) as long precursor transcripts 
(pri-miRNAs). These long pri-miRNAs are cleaved by RNase III 
enzyme Drosha and DGCR8. Pre-miRNAs are exported from the 
nucleus to the cytoplasm by the XPO5/RanGTP heterocomplex. 
Complex in cytoplasm compromised of Dicer RNase III endo-
nuclease and TRBP. Protein further cleaves the pre-miRNA 
generating a short double-stranded miRNA:miRNA complex 
intermediate. miRNA/miRNA duplex, only one strand,designated 
the miRNA strand, is selected as the guide of mature RISC and 
target RNA cleavage by AGO2 is coupled
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sion in human malignancies and proposed that these 
defects clarify a distinct subclass of Wilms tumors [38]. 
However, several investigations have revealed that 
dysregulation of Dicer gene are observed in many 
disorders, including upregulation in Dicer1 gene ex-
pression with tumor stages and progression of prostate 
cancer and smooth muscle tumors [39]. In addition, 
preliminary investigations revealed that upregulation 
of Dicer1 is correlated with gastric tumor subtype and 
advanced tumor stages in gastric cancer and serous 
ovarian cancer [40, 41]. However, the other studies 
showed that the increased Dicer1 expression levels 
are required for proliferation of oral cancer cells [42]. 
Faber et al. [43] evaluated Dicer1 expression levels 
in colorectal cancer, and revealed an increased level, 
which is associated with tumor stage and poor survival 
of the patients. Chiosea et al. [44] disclosed that up-
regulation of Dicer1 expression levels are associated 
with histological subtypes and stages of lung cancer. 
Ma et al. [45] showed that up-regulated Dicer1 expres-
sion levels correlated with clinical stage of cutaneous 
melanoma. In general, Dicer expression levels are 
different in various cancer types; Witkowski et al. [46] 
revealed that downregulation of Dicer1 expression 
levels is associated with the altered miRNA profile 
in patients with bladder cancer. Pampalakis et al. [47] 
revealed that decreased Dicer1 expression levels 
are associated with advanced tumor stage and poor 
survival of ovarian cancer patients. Contradictory 
to the other findings, Torres et al. [48] showed that 
downregulation of Dicer1 gene is not associated with 
histological grade in patients with endometrial cancer. 
Guo et al. [49] observed the decreased expression 
of Dicer1, which correlated with lower survival of pa-
tients with nasopharyngeal carcinoma. In addition, Lin 
et al. [50] revealed that Dicer1 expression levels were 
significantly lower and associated with total downregu-
lation of miRNAs and poor outcome of patients with 
neuroblastoma. Khoshnaw et al. [51] revealed that 
decreased Dicer1 expression levels are associated 
with breast cancer (BC) progression and recurrence. 
Furthermore, investigations displayed that decrease 
of Dicer1 levels are correlated with metastasis, in-
vasion and poor prognosis and shortened survival 
in the patients with gallbladder adenocarcinoma and 
non-small cell lung cancer [52, 53]. Wu et al. [54] 
revealed that downregulation of Dicer1 is not asso-
ciated with clinical characteristics of hepatocellular 
carcinoma (HCC). Findings in other studies revealed 
that decreased Dicer1 expression levels are associ-
ated with progression, tumor stage, prognosis and 
shorter survival of patients with chronic lymphocytic 
leukemia, colorectal cancer, BC, and papillary thyroid 
carcinoma (Table) [55–59].
DROSHA
Drosha involves two RNase III domains, which 
performs a vital role in miRNA biogenesis; Drosha 
and its double-stranded RNA-binding partner protein 
Pasha/DGCR8 likely identify and cut miRNA precursor 
RNAs or pri-miRNA hairpins co-transcriptionally [60]. 
Long pri-miRNAs are cleaved by microprocessor 
complex comprising of Drosha, a type III ribonucle-
ase (RNase III), and an RNA-binding protein DGCR8, 
is so called because a Drosha/DGCR8 complex 
is essential and sufficient to process a pri-miRNA 
into a pre-miRNA hairpin in vitro. Dicer then cleaves 
the pre-miRNA hairpin at the loop to form the mature 
miRNA. Correct Drosha cleavage in the pri-miRNA 
is critical to the production of a functional miRNA [61]. 
Drosha is an important factor for miRNA biogenesis 
and as such obligatory for cellular homeostasis and 
developmental processes. Together with its cofactor 
DGCR8, it changes the pri-miRNA into the pre-miRNA 
in the nucleus. Whilst the middle and the C-terminal 
domain are important for pri-miRNA processing and 
DGCR8 binding, the activity of the N-terminus remains 
mysterious. Different investigations have linked this 
region to the subcellular localization of Drosha, stabi-
lization, and response to tension [62]. The repression 
occurs solely in mature miRNAs and not in pri-miRNA 
transcripts, evidencing that the Drosha E1147K muta-
tion affects processing of pri-miRNAs. The pivotal role 
of the miRNA biogenesis pathway is shown in Wilms 
tumor development, particularly the major miRNA 
processing gene Drosha [63]. Decreased expres-
sion of Drosha was found in melanoma. Furthermore, 
the irregular subcellular location of Drosha reveals 
potential deregulation in the procedures responsible 
for its proper localization in the nucleus [64]. The new 
results show that cytoplasmic Drosha potentially plays 
a role in blocking carcinogenesis and progression 
of gastric cancer and may serve as an independent 
prognostic marker [65]. The copy number discrepancy 
of Dicer1 and Drosha correlates well with their expres-
sion levels and survival of patients with non-small cell 
lung cancer and other cancer types. The increased 
expression of Drosha and Dicer1 are associated 
with decreased and increased survival, respectively. 
As a result, copy number variation may be a sig-
nificant mechanism of upregulation/downregulation 
of miRNAs in malignancy and propose an oncogenic 
role for Drosha [66]. Muralidhar et al. [39] revealed that 
upregulation of Drosha expression levels could alter 
miRNA profile associated with neoplastic progression 
in cervical squamous cell carcinoma (SCC). In ad-
dition, Sugito et al. [67] have shown that increased 
Drosha expression was associated with poor sur-
vival of patients with esophageal cancer. The findings 
of several investigations have shown that upregulation 
of Drosha was associated with tumor progression, 
advanced tumor stages and poor prognosis in the pa-
tients with various cancer types [37–39, 51]. Moreover, 
Sand et al. [68] revealed that upregulation of Drosha 
expression levels was not determined in SCC and 
basal cell carcinoma (BCC). Avery-Kiejda et al. [69] 
revealed that upregulation of Drosha expression levels 
had no significant clinical correlation in triple-negative 
BC. Similarly, in others investigations, findings showed 
that downregulation of Drosha expression levels could 
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alter miRNA profile and correlated with poor patient 
survival, histological grade, metastasis, invasion and 
poor prognosis in many cancer types [48–50, 52, 64, 
70, 71]. Findings revealed that altered Drosha expres-
sion levels are not associated with clinical features 
in colorectal cancer, BC, and papillary thyroid carci-
noma (see Table) [57–59].
DGCR8
Mirtrons pathways include a small class of miRNAs; 
although miRNAs are synthesized via the miRtron 
pathway rather than by Drosha, the synthesis of main 
miRNAs looks to be Drosha dependent. The prominent 
stem-loop in pri-miRNAs is identified through Dro-
sha together with its partner Pasha/DGCR8. Indeed, 
Pasha/DGCR8 is thought to bind preferentially at the 
junction between the stem and the more inflexible 
loop, and this process can be co-transcriptional. 
This binding then positions Drosha midway up to the 
stem so that it is correctly positioned to make a pair 
of staggered breaks to generate the nearly 70 bp pre-
miRNA [72]. The microprocessor complex mediates 
intranuclear biogenesis of pre-miRNAs from the pri-
miRNA transcript. Extranuclear, mature miRNAs are 
merged into the RISC before interaction with complet-
ing target mRNA that leads to repression of translation 
Table. Patterns of miRNA expression in different tumor types
Genes Increase or decrease Cancer type Refs
Drosha Altered miRNA profile; associated with neoplastic progression Cervical SCC [39]
Regulates cell proliferation; associated with poor patient survival Oesophageal cancer [67]
Associated with pathological characteristics and patient survival Gastric cancer [40]
Associated with advanced tumor stages Serous ovarian carcinoma [41]
Associated with poor prognosis Non-small cell lung cancer [53]
Not determined SCC and BCC [68]
No clinical correlation Triple-negative BC [69]
Altered miRNA profile Bladder cancer [70]
Associated with poor patient survival Ovarian cancer [71]
Correlated with histological grade Endometrial cancer [48]
Correlated with shorter patient survival Nasopharyngeal carcinoma [49]
Correlated with metastasis, invasion and poor prognosis Gallbladder adenocarcinoma [50]
Correlated with total downregulation of miRNAs and poor outcome Neuroblastoma [52]
Associated with cancer progression and poor survival Cutaneous melanoma [64]
Down-regulated BC [58]
Significantly upregulated, not associated with clinical characteristics Colorectal cancer [57]
Significantly lower expressed, not associated with clinical characteristics Papillary thyroid carcinoma [59]
Dicer Correlated with a gastric tumor subtype
Gastric cancer [40]
Associated with advanced tumor stages Serous ovarian carcinoma [41]
Required for proliferation Oral cancer [42]
Correlated with tumor stage and associated with poor survival Colorectal cancer [43]
Associated with histological subtypes and stages Precursor lesions of lung adenocarcinoma [44]
Correlated with clinical stage Cutaneous melanoma [45]
Altered miRNA profile Bladder cancer [46]
Associated with advanced tumor stage and poor patient survival Ovarian cancer [47]
No association with histological grade detected Endometrial cancer [48]
Correlated with shorter patient survival Nasopharyngeal carcinoma [49]
Associated with a total down regulation of miRNAs and poor outcome Neuroblastoma [50]
Associated with cancer progression and recurrence BC [51]
Correlated with metastasis, invasion and poor prognosis Gallbladder adenocarcinoma [52]
Low levels of DICER1 expression correlate with shortened survival Non-small cell lung cancer [53]
Not associated with clinical characteristics HCC [54]
Associated with progression and prognosis Chronic lymphocytic leukemia [55]
Associated with tumor stage and shorter survival Colorectal cancer [56]
Significantly upregulated, not associated with clinical characteristics Colorectal cancer [57]
Significantly altered gene expression, not associated with clinical char-
acteristics
Papillary thyroid carcinoma [59]
Down-regulated BC [58]
DGCR8 Associated with poor patient survival Oesophageal cancer [67]
Altered miRNA profile Bladder cancer [70]
Not determined SCC and BCC [68]
Associated with dysregulated miRNA Prostate cancer [64]
Not associated with any clinical parameters Colorectal carcinoma [73]
Required for cell proliferation, migration and invasion Ovarian cancer [75]
Significantly altered gene expression, not associated with clinical char-
acteristics
Papillary thyroid carcinoma [59]
XPO5 Associated with an altered miRNA profile Bladder cancer [70]
AGO1/AGO2 Not determined Actinic keratoses, SCC and BCC [68]
Associated with advanced tumor stages Serous ovarian carcinoma [41]
Correlated with advanced tumor stages and associated with shorter sur-
vival
Significantly lower expressed, not associated with clinical characteristics Papillary thyroid carcinoma [59]
TRBP Amplified in BC BC [85]
Significantly up-regulated, associated with clinical characteristics BC [87]
Significantly up-regulated Malignant melanoma [88]
Significantly up-regulated Diffuse large B cell lymphomas [96]
Significantly up-regulated, not associated with histopathological and 
clinical parameters
Adrenocortical carcinoma [97]
Altered miRNA profile Ewing sarcoma [98]
Notes: AGO — Argonaute; BC — breast cancer; BCC — basal cell carcinoma; DGCR8 — DiGeorge syndrome critical region 8; SCC — squamous cell carcino-
ma; XPO5 — exportin-5; TRBP — transactivation-responsive RNA-binding protein.
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or mRNA destabilization. The DGCR8 is a component 
of microprocessor complex crucial for miRNA matura-
tion. The Ago2 proteins are a component of a complex 
protein named as RISC. A previous investigation has 
shown that DGCR8 mRNA expression is down-regu-
lated in prostate cancer. Upregulated DGCR8 mRNA 
expression has been found in epithelial skin cancer and 
pleomorphic adenomas of the salivary gland. It has 
been documented that the Ago2 mRNA expression 
level is up-regulated in epithelial skin cancer [73]. 
Firstly, the DGCR8 mRNA expression level was up-reg-
ulated in colorectal cancer, evidencing on its role in the 
pathobiology of the colorectal carcinogenesis [74]. 
DGCR8 was expressed in ovarian cancer. MiR-27b 
was detected as significantly down-regulated miRNA 
in DGCR8-knockdown cells and endorsed cell prolif-
eration in ovarian cancer cells [75]. Preliminary stud-
ies reported that expression levels of Drosha in AGS 
and HepG2 cell lines were higher than in the controls, 
whereas, Drosha expression level in KYSE-30 cell line 
was lower. The Dicer expression levels in AGS and 
HepG2 cells were increased, whereas, its expression 
level in KYSE-30 cell was lower. The DGCR8 expression 
levels in all three cell lines were significantly higher 
than in the control samples [76]. In addition, Sugito 
et al. [67] revealed that upregulation of DGCR8 ex-
pression was associated with poor survival of patients 
with esophageal cancer. Catto et al. [70] showed that 
increased DGCR8 expression levels altered the miRNA 
profile in bladder cancer. Sand et al. [68] reported that 
upregulation of DGCR8 expression was not determined 
in SCC and bladder cancer, additionally, revealed that 
up-regulated DGCR8 expression was associated with 
dysregulated miRNA in prostate cancer. Kim et al. [73] 
revealed that upregulation of DGCR8 expression was 
not associated with any clinical parameters in colorec-
tal carcinoma. Furthermore, Guo et al. [49] revealed 
that increased DGCR8 expression levels were required 
for cell proliferation, migration, and invasion in ovarian 
cancer. Findings revealed that altered DGCR8 expres-
sion is not associated with clinical features in papillary 
thyroid carcinoma [59].
AGO
Pre-miRNAs exported into the cytoplasm are pro-
cessed by another RNase III enzyme, Dicer, into nearly 
21 bp double-stranded miRNA-miRNA duplexes and 
moved into the groove of AGO. Afterwards the miRNA 
strand dissociation, mature single-stranded miRNA 
remains loaded into and stabilized by AGO1. AGO was 
subsequently separated from Dicer to bind TNRC64, 
an essential co-factor in the miRNA-induced silenc-
ing complex [77]. AGO2 is a major part of the RISC 
that can directly deteriorate mRNA through slicing 
AGO2 amasses in cytoplasmic processing bodies, 
where additional binding interactions promote transla-
tional inhibition and mRNA decay. AGO2 also couples 
with MVEs in structures that have been called “GW-
bodies” because of the presence of GW182 but lack 
of other P-body components. Current reports have 
demonstrated that AGO2 binds to miRNAs to generate 
AGO2-miRNA complexes that are found in the extra-
cellular space. Although the majority of descriptions 
illustrates Ago2 as being present in the extracellular 
space as a free protein, other investigations have 
shown that AGO2 and other RNA-processing pro-
teins are present in the secreted exosomes [78]. The 
genetic polymorphism of AGO2 may be a risk factor 
for the progressive lymph node metastasis in naso-
pharyngeal carcinoma in the Chinese population, 
and AGO2 acts as an oncogene in the development 
of nasopharyngeal carcinoma [79]. Sand et al. [68] 
revealed that upregulation of AGO1 and AGO2 expres-
sion was not determined in actinic keratosis, SCC and 
BCC, while such upregulation was associated with 
advanced tumor stages in serous ovarian carcinoma. 
Findings revealed that the AGO2 expression levels 
was significantly lower in neoplastic tissues compared 
to the healthy tissues in papillary thyroid carcinoma 
(see Table) [59].
XPO5
XPO5 is a component of the importin-β family 
of proteins that consist of one major class of nucleo-
cytoplasmic transporters. XPO5 binds directly to its 
pre-miRNA cargo in a Ran-GTP-dependent manner. 
As well, XPO5 is capable of recognizing and export 
structured RNAs that are unrelated to pre-miRNAs, 
involving viral mini-helix RNA and tRNA, along with 
certain other proteins, such as STAU2, ILF3, and 
JAZ. It has also been indicated that XPO5 is impor-
tant in siRNA biogenesis and therefore, is a basic 
point of intersection between the siRNA and miRNA 
pathways [80]. XPO5 is a transporter protein regularly 
mediating pre-miRNAs nuclear export. Recent investi-
gations have displayed that XPO5 may play an impor-
tant role in some cancers. Anyway, little is known about 
XPO5 in HCC [81]. The XPO5 genetic defect traps 
pre-miRNAs in the nucleus decreases miRNA pro-
cessing and diminishes miRNA-target inhibition [82]. 
XPO5 knockdown promoted HCC cell migration and 
decreased the expression of E-cadherin and p53. 
Furthermore, after treatment with DAC and TSA, the 
mRNA level of XPO5 was up-regulated in HCC cells, 
implicating that epigenetic modulation may be involved 
in the transcription of XPO5. Generally, these findings 
suggest that XPO5 functions as a potential tumor sup-
pressor in the development and progression of HCC 
as well as a promising molecular target for HCC ther-
apy [83]. Catto et al. [70] revealed that upregulation 
of XPO5 expression was associated with the altered 
miRNA profile in bladder cancer (see Table).
TRBP
miRNAs are transported from the nucleus to the 
cytoplasm via XPO5 mediated pathway, where they 
are bound with Dicer and the TRBP, and maturate into 
double-stranded miRNAs. The active strand of such 
mature miRNA is retained in the Dicer-TRBP com-
plex, which then binds with the endonuclease AGO2. 
One strand of the mature miRNA (the guide strand) 
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is loaded into the RISC target mRNAs that are comple-
mentary to the miRNA [84]. Huang et al. [85] revealed 
that TRBP is overexpressed in BC. TRBP is multi-
functional and mediates crosstalk between different 
pathways. The protein AIB3, also known as ASC-2, 
RAP250, PRIP, TRBP, and NCR, is a newly recognized 
nuclear receptor co-activator that is amplified and 
over-expressed in BC [86]. Lin et al. [87] revealed 
that the BC patients with cytoplasmic overexpression 
of TRBP2 had shorter disease free survival and over-
all survival. Sand et al. [88] showed that TRBP2 was 
significantly up-regulated in benign melanocytic nevi 
compared to primary cutaneous malignant melanoma 
(see Table). Earlier, we have applied a gold standard 
method for lymphoma diagnosis using TRBP2 gene 
expression analysis [89–95]. However, Caramuta 
et al. [96] revealed that the expression of TRBP2 was 
significantly higher in diffuse large B cell lymphomas 
than in lymph nodes, and also in the adrenocortical 
carcinomas compared with adenomas or normal ad-
renal cortices. Whereas, TRBP2 expression was not 
correlated with histopathological and clinical param-
eters [97]. De Vito et al. [98] revealed that deregulation 
of TRBP2 in the Ewing sarcoma.
In conclusion, the newest findings on miRNA ex-
pression patterns in cancerous tissues will allow to de-
velop the use of these molecules as novel biomarkers 
for tumor diagnosis, prognosis, and therapy.
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